Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy

AIDS

Volumn 15, Issue 1, 2001, Pages 17-22

  Sonza, Secondo ^a,c   Mutimer, Helen P ^a,d   Oelrichs, Robert ^a   Jardine, Darren ^b   Harvey, Katya ^a   Dunne, Amanda ^a   Purcell, Damian F ^a   Birch, Christopher ^b   Crowe, Suzanne M ^a  

^a Macfarlane Burnet Centre for Medical Research   (Australia)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH   (Australia)

^d USA   (United States)

Author keywords

Highly active antiretroviral therapy; Monocytes; Recent infection; Viral DNA and RNA expression; Virus recovery

Indexed keywords

ANTIRETROVIRUS AGENT; DIDANOSINE; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ANTIMICROBIAL THERAPY; ARTICLE; CLINICAL ARTICLE; DNA DETERMINATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE ADHERENCE; MONOCYTE; PRIORITY JOURNAL; T LYMPHOCYTE; VIREMIA; VIRUS INFECTIVITY; VIRUS LATENCY; VIRUS LOAD; VIRUS PATHOGENESIS; VIRUS REPLICATION;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-POSITIVE T-LYMPHOCYTES; HIV INFECTIONS; HIV-1; HUMANS; MONOCYTES; VIRUS INTEGRATION; VIRUS LATENCY; VIRUS REPLICATION;

EID: 0035808518     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200101050-00005     Document Type: Article

References (38)

1. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy
2. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy
3. Recovery of replication-competent HIV despite prolonged suppression of plasma viraemia
4. Persistence of HIV-1 transcription in peripheral blood mononuclear cells in patients receiving potent antiretroviral therapy
5. HIV-1 replication in patients with undetectable plasma virus receiving HAART
6. Persistence of episomal HIV-1 infection intermediates in patients on highly active antiretroviral therapy
7. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy
8. Decay characteristics of HIV-1 infected compartments during combination therapy
9. Viral dynamics in HIV-1 infection
10. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy
11. Human immunodeficiency virus type 1 replication is blocked prior to reverse transcription and integration in freshly isolated peripheral blood monocytes
12. Updated proposal of reference sequences of HIV-1 genetic subtypes
13. Quantitative analysis of hepatitis C virus RNA in liver biopsies by competitive reverse transcription and polymerase chain reaction
14. Surface CD4 is critical to in vitro HIV infection of human alveolar macrophages
15. HIV-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells
16. In vivo fate of HIV-1 infected T cells: Quantitative analysis of the transition to stable latency
17. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy
18. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538)
19. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1
20. Genotypic changes in human immunodeficiency virus type 1 associated with loss of suppression of plasma viral RNA levels in subjects treated with ritonavir (Norvir) monotherapy
21. An Escherichia coil expression assay and screen for human immunodeficiency virus protease variants with decreased susceptibility to indinavir
22. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor
23. Pol gene diversity of five human immunodeficiency type 1 subtypes: Evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D
24. Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays
25. Resistance to protease inhibitors
26. CCR5 coreceptor usage of non-syncytium-inducing primary HIV-1 is independent of phylogenetically distinct global HIV-1 isolates: Delineation of consensus motif in the V3 domain that predicts CCR5 usage
27. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy
28. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy
29. HIV-1 proviral DNA copy number in peripheral blood leucocytes and bronchoalveolar lavage cells of AIDS patients
30. Human Kupffer cells infected with HIV-1 in vivo
31. Macrophages as a source of HIV during opportunistic infections
32. Mononuclear phagocyte heterogeneity and the blood-brain barrier: A model for HIV-1 neuropathogenesis
33. Bone marrow derived elements and resident microglia in brain inflammation
34. In vitro blood brain barrier permeability of nevirapine to other HIV antiretroviral agents
35. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors
36. In vitro activity of inhibitors of late stages of the replication of HIV in chronically infected macrophages
37. Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus
38. Induction of HIV-1 replication in latently infected CD4+ T cells using a combination of cytokines